Assenagon Asset Management S.A. Sells 387,872 Shares of ADMA Biologics Inc $ADMA

Key Points

• Assenagon Asset Management S.A. has reduced its position in ADMA Biologics Inc by 97.0%, selling 387,872 shares and now holding only 12,050 shares.
• The firm reported a net margin of 44.06% and a quarter earnings per share of $0.15, beating estimates by $0.01, with revenues up 13.8% from the previous year.
• ADMA Biologics' stock is trading at $15.61, with a market capitalization of $3.73 billion and has shown volatility, with a 12-month high of $25.67 and a low of $13.50.

Assenagon Asset Management S.A. lowered its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 97.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,050 shares of the biotechnology company's stock after selling 387,872 shares during the quarter. Assenagon Asset Management S.A.'s holdings in ADMA Biologics were worth $219,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of ADMA Biologics in the first quarter valued at about $35,000. SVB Wealth LLC bought a new position in ADMA Biologics in the first quarter worth approximately $35,000. Smartleaf Asset Management LLC grew its stake in ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 1,493 shares in the last quarter. Tsfg LLC purchased a new stake in ADMA Biologics during the first quarter worth $51,000. Finally, Brooklyn Investment Group lifted its holdings in ADMA Biologics by 28,655.6% during the first quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock worth $51,000 after buying an additional 2,579 shares during the period. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Performance

Shares of ADMA opened at $15.61 on Monday. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The stock has a fifty day moving average price of $17.02 and a 200-day moving average price of $18.89. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.73 billion, a PE ratio of 18.15 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the prior year, the business posted $0.13 EPS. The business's revenue for the quarter was up 13.8% compared to the same quarter last year. Equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.